Topic Highlight
Copyright ©2014 Baishideng Publishing Group Co.
World J Gastroenterol. Mar 28, 2014; 20(12): 3059-3068
Published online Mar 28, 2014. doi: 10.3748/wjg.v20.i12.3059
Table 2 Comparison of European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors 1.1
EORTCPERCIST
CMRComplete resolution of 18F-FDG uptake within the tumor volume so that it is indistinguishable from surrounding normal tissueComplete resolution of 18F-FDG uptake within measurable target lesion so that the liver activity was less than the mean and indistinguishable from surrounding background blood-pool levels plus disappearance of all other lesions to background blood pool levels and appearance of no new 18F-FDG-avid lesions
PMRMinimum 15%-25% reduction in tumor 18F-FDG SUV after 1 chemotherapy cycle and > 25% reduction after ≥ 1 treatment cycle; reduction in extent of tumor 18F-FDG uptake not required≥ 30% relative and ≥ 0.8 SUL unit absolute reduction in target measurable tumor 18F-FDG SUL peak and no increase > 30% in SUL or size (per RECIST) of target or nontarget lesions or appearance of new lesions; reduction in extent of tumor 18F-FDG uptake not required ≥ 30% decrease in the sum of the longest diameters
SMD< 25% increase or < 15% decrease in tumor 18F-FDG SUV and no visible increase in extent of 18F-FDG tumor uptake (> 20% in the longest dimension)Not CMR, PMR, nor PMD
PMD> 25% increase in 18F-FDG tumor SUV within the tumor region defined on the baseline examination or visible increase in the extent of 18F-FDG tumor uptake (> 20% in the longest dimension) or appearance of new 18F-FDG uptake in metastatic lesions> 30% increase in 18F-FDG SUL peak, with > 0.8 SUL unit increase in tumor SUV peak from baseline scan in pattern typical of tumor and not of infection/treatment effect or visible increase in extent of 18F-FDG tumor uptake (75% in total lesion glycolysis volume with no decline in SUL) or new 18F-FDG-avid lesions typical of cancer and not related to treatment effect or infection
CMR: Complete metabolic response; PMR: Partial metabolic response; SMD: Stable metabolic disease; PMD: Progressive metabolic disease; EORTC: European Organization for Research and Treatment of Cancer; PERCIST: Positron Emission Tomography Response Criteria in Solid Tumors; FDG: Fluorodeoxyglucose; SUV: Standardized uptake values.